Plant secondary metabolites have emerged as invaluable resources in pharmaceutical sciences, contributing significantly to drug discovery, development, and therapeutic innovation. These structurally diverse bioactive compounds, including alkaloids, flavonoids, terpenoids, and phenolic compounds, exhibit a broad spectrum of pharmacological activities ranging from anticancer and antimicrobial effects to anti-inflammatory and neuroprotective properties. This comprehensive review examines the classification, biosynthesis, and mechanisms of action of major secondary metabolite classes, highlighting their interactions with molecular targets such as enzymes, receptors, signaling pathways, and gene expression regulators. We synthesize preclinical evidence from in vitro and animal studies demonstrating dose-dependent efficacy and mechanistic insights, alongside clinical evidence supporting therapeutic applications in oncology, cardiovascular disease, metabolic disorders, and neurodegenerative conditions. The article addresses critical challenges in translating these natural products into clinical practice, including formulation strategies for enhanced bioavailability, safety considerations encompassing toxicity and herb-drug interactions, and regulatory frameworks for standardization and quality control. Emerging technologies such as nanotechnology-based delivery systems, metabolic engineering, and systems pharmacology approaches are discussed as promising avenues for optimizing therapeutic outcomes. By integrating traditional ethnopharmacological knowledge with modern pharmaceutical sciences, this review provides a comprehensive framework for advancing plant secondary metabolites from bench to bedside, emphasizing their potential to address unmet medical needs and contribute to precision medicine initiatives in the evolving landscape of drug development.